Rachael A Cohen1, Jerome H Check2,3, Michael P Dougherty4. 1. Department of Obstetrics and Gynecology, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA. 2. Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Cooper Medical School of Rowan University, Camden, NJ, USA. laurie@ccivf.com. 3. , 7447 Old York Road, Melrose Park, PA, 19027, USA. laurie@ccivf.com. 4. Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Abstract
PURPOSE: To determine if exposure to progesterone alone is sufficient to increase the production of the immunomodulatory protein known as the progesterone induced blocking factor (PIBF). Also to determine what method of progesterone delivery or form of P best stimulates PIBF secretion. METHODS: Serum samples from patients with infertility and paid volunteers were evaluated for both PIBF and progesterone at various times during the follicular phase and the luteal phase in both natural cycles and cycles involving embryo transfer after endogenous and exogenous progesterone exposure and after various synthetic progestins. PIBF was measured by a non-commercial research ELISA assay. Comparisons were made of serum PIBF before and after exposure to progesterone, 17-hydroxyprogesterone, and oral contraceptives. PIBF was also measured before and after transfer of embryos. RESULTS: Progesterone alone without exposure to the fetal allogeneic stimulus was able to produce a marked increase in serum PIBF. Neither a synthetic progestin (19-nortestosterone derivative) nor 17-hydroxyprogesterone caused an increase in PIBF. Some PIBF is generally detected even in the follicular phase. CONCLUSIONS: A previous concept considered that an allogeneic stimulus, e.g., from the fetal semi-allograft, was necessary to induce de novo progesterone receptors in gamma delta T cells, which, in turn, when exposed to a high concentration of progesterone, would secrete high levels of PIBF. These data show that exposure to an allogeneic stimulus is not needed to cause a marked rise in PIBF, merely progesterone alone is sufficient.
PURPOSE: To determine if exposure to progesterone alone is sufficient to increase the production of the immunomodulatory protein known as the progesterone induced blocking factor (PIBF). Also to determine what method of progesterone delivery or form of P best stimulates PIBF secretion. METHODS: Serum samples from patients with infertility and paid volunteers were evaluated for both PIBF and progesterone at various times during the follicular phase and the luteal phase in both natural cycles and cycles involving embryo transfer after endogenous and exogenous progesterone exposure and after various synthetic progestins. PIBF was measured by a non-commercial research ELISA assay. Comparisons were made of serum PIBF before and after exposure to progesterone, 17-hydroxyprogesterone, and oral contraceptives. PIBF was also measured before and after transfer of embryos. RESULTS:Progesterone alone without exposure to the fetal allogeneic stimulus was able to produce a marked increase in serum PIBF. Neither a synthetic progestin (19-nortestosterone derivative) nor 17-hydroxyprogesterone caused an increase in PIBF. Some PIBF is generally detected even in the follicular phase. CONCLUSIONS: A previous concept considered that an allogeneic stimulus, e.g., from the fetal semi-allograft, was necessary to induce de novo progesterone receptors in gamma delta T cells, which, in turn, when exposed to a high concentration of progesterone, would secrete high levels of PIBF. These data show that exposure to an allogeneic stimulus is not needed to cause a marked rise in PIBF, merely progesterone alone is sufficient.
Authors: Beata Polgar; Gyula Kispal; Margit Lachmann; Christian Paar; Eszter Nagy; Peter Csere; Eva Miko; Laszlo Szereday; Peter Varga; Julia Szekeres-Bartho; Gabriella Paar Journal: J Immunol Date: 2003-12-01 Impact factor: 5.422
Authors: Margit Lachmann; Dieter Gelbmann; Endre Kálmán; Beata Polgár; Michael Buschle; Alexander Von Gabain; Júlia Szekeres-Barthó; Eszter Nagy Journal: Int J Cancer Date: 2004-10-20 Impact factor: 7.396
Authors: Tim Ott; Lilian Kaufmann; Martin Granzow; Katrin Hinderhofer; Claus R Bartram; Susanne Theiß; Angelika Seitz; Nagarajan Paramasivam; Angela Schulz; Ute Moog; Martin Blum; Christina M Evers Journal: Front Physiol Date: 2019-02-25 Impact factor: 4.566
Authors: Nishel Mohan Shah; Anna A Herasimtschuk; Adriano Boasso; Adel Benlahrech; Dietmar Fuchs; Nesrina Imami; Mark R Johnson Journal: Front Immunol Date: 2017-09-15 Impact factor: 7.561